Table 3.
Proteins expressed at significantly different levels in CVF samples from spontaneous preterm birth cases and term delivery controls.
| Protein | Peptides | Fold Change | +/− | P |
|---|---|---|---|---|
| Second Study Visit (190/7–236/7 wk) | ||||
| Laminin alpha 3 subunit isoform | 2 | 2.6 | + | 0.05 |
| Cystatin C precursor | 2 | 2.3 | + | 0.002 |
| Laminin A/C isoform 2 | 2 | 1.8 | + | 0.05 |
| Calsyntenin 1 isoform 2 | 1 | 1.7 | + | 0.007 |
| Third Study Visit (280/7–316/7 wk) | ||||
| Extracellular matrix protein 1 isoform 1 precursor | 2 | 4.7 | + | 0.02 |
| Tissue inhibitor of metalloproteinase 1 precursor | 2 | 1.7 | − | 0.05 |
| HSP-beta 1 | 1 | 1.9 | − | 0.04 |
| Calsyntenin 1 isoform 2 | 1 | 2.3 | − | 0.05 |
| Laminin alpha 3 subunit isoform | 1 | 2.2 | − | 0.04 |
| Urokinase plasminogen activator preprotein | 1 | 2.1 | − | 0.05 |
| Both Visits | ||||
| Fibronectin-1 | 2 | 1.7 | + | 0.05 |
| Extracellular matrix protein 1 isoform 1 precursor | 2 | 2.3 | + | 0.02 |
| Laminin alpha 3 subunit isoform | 2 | 2.5 | + | 0.03 |
| Laminin A/C isoform 2 | 2 | 1.7 | + | 0.04 |
| Desmoplakin isoform 1 | 1 | 1.5 | − | 0.03 |
| Calsyntenin 1 isoform 2 | 1 | 1.4 | + | 0.02 |
Peptides: number of peptides for each protein demonstrating different L/H (light endogenous peptide area/heavy stable isotope labeled proteome [SILAP] peptide area); +/−: increase/decrease;
P values: determined by two-sample t tests.